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1069-107 Hospitalizations in Heart Failure: It's Not What You 
Think
Peter Carson, Christopher M. O'Connor, Alan Miller, Jay N. Cohn, Department of Veterns 
Affairs Medical Center, Washington, DC
Hospitalization for heart failure (HFH) is a major component of morbidity of this disease.
We recently reported that, from the ValHeFT data, HF represented a minority of all hospi-
talization –38% placebo group (J. Card. Failure 9:164; 2003). We have reviewed pub-
lished hospitalization results in the placebo groups of major trials spanning mild-to-
advanced HF to assess the proportion of HF hospitalizations. We also assessed relative
hospitalization rates for HF and all cause(AC) by using published follow-up (FU) (mean in
all studies except CHARM and ATLAS) to estimate exposure time.. 
N= number of randomized patients; EF= ejection fraction; AMR= annual mortality rate: 
FU= follow-up; HFH/Pt/mm= HFH per randomized patient per month
HF is an important cause of hospitalization in HF patients, but are usually a minority of 
events. The proportion of AC hospitalizations that are HF are remarkably constant in 
mild-moderate HF, but increase with advanced HF. AC hospitalizations are also relatively 
constant, although appear to increase with HF severity. In all studies, non HF hospitaliza-
tions, both CV and nonCV, are the dominant component of hospitalization. They require 
further study to determine whether HF therapy can affect this part of the “burden” of heart 
failure.
1069-108 Systolic Heart Failure Is Associated With a Significantly 
Worse Long-Term Survival Than Diastolic Heart Failure 
Among Patients With Coronary Artery Disease
Jeffrey S. Berger, Warren Sherman, Timothy A. Sanborn, David L. Brown, Beth Israel 
Medical Center, New York, NY
Background: Heart failure (HF) in the setting of coronary artery disease (CAD) is asso-
ciated with impaired survival. However, the relative contribution of diastolic (DHF) versus
systolic heart failure (SHF) to the adverse prognosis is unknown. We sought to compare
the impact of diastolic versus systolic dysfunction on survival in patients with HF and
CAD.
Methods: Of 4284 consecutive patients with CAD undergoing PCI at 3 hospitals in New
York City from 1998-1999, 466 patients with previous or current HF and known ejection
fractions (EF) comprised the study population. DHF was defined by an EF > 50% and
SHF by an EF < 50%. All-cause mortality at a mean follow-up of 3 years was the primary
endpoint.
Results: Of the 466 patients with HF, 147 (32%) had DHF. The mean EFs were 56.4 ±
6.8% in the DHF and 37.1 ± 9.1% in the SHF group (P<0.001). Both groups were of sim-
ilar age. DHF patients were more often female (45% vs. 35%, P=0.051). Hypertension,
diabetes, stroke, peripheral vascular disease, renal insufficiency and smoking were simi-
lar in both groups. Patients with DHF were less likely to have a prior myocardial infarction
(8.2% vs. 15.0%, P=0.039). One-vessel CAD was more often associated with DHF (40%
vs. 27%, P=0.003) whereas 3-vessel CAD was more common in SHF patients (32% vs.
23%, P=0.044). Stents were placed in approximately 75% of patients in both groups and
GP IIb/IIIa receptor inhibitors were administered to 25% of patients in each group. Angio-
graphic success was 97% in both groups. In-hospital mortality was 1.4% and 3.8% in the
DHF and SHF population, respectively (P=0.158). The 3-year mortality was greater in
patients with SHF than in those with DHF (30% vs. 10%, P<0.001). On Cox proportional
hazards analysis SHF was associated with a significant independent increase in the haz-
ard of late mortality (Hazard Ratio, 4.80, 95% Confidence Interval, 2.38-9.68, P<0.001).
Conclusion: Patients with CAD and SHF have an approximately 5-fold increase in the
hazard of late mortality following PCI compared to those with CAD and DHF. These find-
ings suggest that the optimum treatment for patients with SHF following PCI is not known
and may require greater integration of revascularization and implantable defibrillator
strategies.
1069-109 Individualized Prediction of Heart Failure Survival: An 
Analysis From PRAISE1
Wayne C. Levy, Dariush Mozaffarian, Regina G. Nye, Anne Cropp, University of 
Washington, Seattle, WA, Pfizer, Groton, CT
Previous heart failure (HF) risk models stratify patients into 3 risk groups using peak oxy-
gen consumption (VO2). An individualized estimate of survival in HF has not been
reported. We retrospectively investigated predictors of survival among 1,125 HF patients
in PRAISE1 (NYHA 3B-4, EF<30%, ACEI, digoxin, diuretics, 403 deaths). A stepwise
Cox proportional hazard model was used to identify multivariate predictors of risk; the
final model included age, gender, ischemic etiology, NYHA class, ejection fraction, sys-
tolic blood pressure, K-sparing diuretic use, statin use, allopurinol use, hemoglobin, %
lymphocyte count, uric acid, sodium, cholesterol, and diuretic dose/kg. Using this model,
the predicted survival for individual patients was compared to the actual survival (mean
1-year predicted survival = 74% ± 17%, Range 3%-97%). The lowest risk decile had an
estimated 1- and 2-year survival of 92% and 84%, respectively, and the actual survival
was 95% and 82%. The highest risk decile had an estimated 1- and 2-year survival of
36% and 13%, respectively, and the actual survival was 30% and 16%. The hazard ratio
for the highest risk decile was 12-fold greater than for the lowest risk decile.
We have developed an individualized estimation of survival in HF using easily obtained
clinical and laboratory values without measurement of peak VO2. We are attempting to
validate the model in other large heart failure cohorts and to add ACEIs, ARBs, B-block-
ers, and devices to the model.
1069-110 Predictors of Mortality in 1,346 Patients With Heart 
Failure Scheduled for Guideline-Based Treatment
Heinz Voeller, Clemens Dovifat, Bettina Ehrlich, Simone Schulz, Kirsten Stolze, Wolfgang 
Kamke, Karl Wegscheider, Klinik am See, Rüdersdorf, Germany, Institut for Statistics and 
Econometry, Hamburg, Germany
The prognosis of patients (P) with heart failure has been shown to improve in controlled
studies with ACE inhibitors and/or beta blockers. The extent to which treatment guide-
lines isussed by professional organisations are implentable in daily clinical practice is
unknown, as are the effects on prognosis and mortality predictors.
Methods:
1346 consecutive patients (64 ±10 years, 27% women) with an ejection fraction (EF) <
45% (mean EF 36.3±6%) were enrolled in the study (between 01/98 and 12/00). The eti-
ology of the cardiomyopathy was ischemic in 77%, valvular in 6.5% and due to other
causes in 16.5% of the cases. 15.5% of the patients had atrial fibrillation. During inpatient
rehabilitation resting ECG, exercise testing, Holter monitoring with heart rate (HR) vari-
ability, echocardiogram to determine LV diameter, LV filling (E/A), mitral insufficiency and
pulmonary hypertension, and a 6-minute walk-test were performed. The drug therapy
was noted at the time of discharge. The patients were followed for 731 days.
Results:
89%/10 % of the patients received ACE inhibitors/AT1-blockers, 82 % beta blockers, 8 %
amiodarone, 57 % diuretics , and 35 % digitalis. Overall mortality was 11 %, cardiac mor-
tality was 6 %. Significant differences were observed in sinus rhythm (85.3 % survivors
vs. 68.4 % nonsurvivors), number of VES/h (140 vs. 205), heart rate variability (SDANN
71.2 vs. 65.7), systolic diameter on 2 D-echo (LVSD 47.7 vs. 51.5 mm), E/A in the trans-
mitral flow pattern (1.46 vs. 1.79), maximum exercise capacity (76.3 W vs. 57.9 W) and
6-minute walk test (375 m vs. 302 m). Statins and BMI (kg/m2) did not differ. Multivariate
analysis showed that age, pulmonal hypertension, atrial fibrillation, mitral insufficieny,
higher NYHA grade, necessity of diuretics and digitalis, a short distance in the 6-minute
walk test and low exercise capacity were associated with a significantly higher mortality.
Conclusion:
Guideline-based therapy could be established in approximately 90 % of patients with
heart failure and was associated with improved prognosis. While physical fitness was
beneficial for the prognosis, symptomatic therapy was related to poorer outcome.
1069-111 Depression Predicts Mortality and Hospitalization in 
Patients With Acute Myocardial Infarction Complicated 
by Heart Failure: Data From the EPHESUS Trial
John S. Rumsfeld, Philip Jones, Mary A. Whooley, Mark D. Sullivan, Bertram Pitt, William 
S. Weintraub, John A. Spertus, Denver VA Medical Center, Denver, CO, University of 
Missouri-Kansas City, Kansas City, MO
Background: We evaluated depression as a predictor of all-cause mortality and cardio-
vascular mortality or hospitalization in patients with acute myocardial infarction compli-
cated by heart failure.
Methods: In addition to clinical data, patients in the EPHESUS trail (NEJM
2003;102:2700-2706) completed a Medical Outcomes Study-Depression (MOS-D) ques-
tionnaire at baseline. Mean follow-up was 16 months. Primary outcomes were a) all-
cause mortality; and b) cardiovascular death or hospitalization. Kaplan-Meier curves
were used to examine the unadjusted relationship between depression and outcomes.
Cox proportional hazards regression was used to assess the relationship between
depression and outcomes, adjusting for baseline clinical variables.
Results: 143/634 patients (22.6%) had significant depressive symptoms at baseline
(MOS-D score >0.06). In unadjusted analysis, depression was significantly associated
with both all-cause mortality and cardiovascular death or hospitalization (Figure). After
risk adjustment, depression remained associated with all-cause mortality (HR 1.75; 95%
CI 1.15-2.68; p=0.01) and cardiovascular death or hospitalization (HR 1.39; 95% CI 1.02-
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HFH/PT/mo AC Hosp H/PT/mo
CHARM-Preserved 1509 54 5.2 36.6 566 22.2 0.07 2545 0.046
CHARM-ACEI Intol 1015 30 10.9 33.7 608 33 0.017 1835 0.053
CHARM-added 1272 28 9.4 41 836 30 0.016 2798 0.053
SOLVD Tx 1284 24.8 11.6 41 971 34 0.018 2833 0.053
ATLAS 1596 24 11.7 46 1576 35 0.02 4397 0.06
MERIT 2001 28 10.0 12 451 39 0.018 1149 0.047
DIG 3403 28 11.3 37 2553 37 0.02 6277 0.053
VALHEFT 2499 27 9.5 23 1189 38 0.02 3106 0.054
COPERNICUS 1133 20 16.7 10.4 441 53 0.037 827 0.07
VEST 1277 21 24.1 9.5 614 48 0.050 1260 0.10
